TELO
HEALTHCARETelomir Pharmaceuticals Inc
$1.34+0.01 (+0.75%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TELO Today?
No stock-specific AI insight has been generated for TELO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.05$3.10
$1.34
Fundamentals
Market Cap$92M
P/E Ratio—
EPS$-0.33
Dividend Yield—
Dividend / Share—
ROE-3.2%
Profit Margin—
Debt / Equity—
Trading
Volume129K
Avg Volume (10D)—
Shares Outstanding68.8M
TELO News
20 articles- Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast CancerYahoo Finance·Apr 30, 2026
- Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)Yahoo Finance·Apr 24, 2026
- Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple MyelomaYahoo Finance·Apr 14, 2026
- Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast CancerYahoo Finance·Mar 31, 2026
- Telo Genomics Announces Appointment of John Farlinger as CEO and ChairmanYahoo Finance·Mar 31, 2026
- Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer ModelsYahoo Finance·Feb 17, 2026
- Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and AgingYahoo Finance·Feb 5, 2026
- Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal ModelsYahoo Finance·Jan 5, 2026
- Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical DevelopmentYahoo Finance·Dec 18, 2025
- Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer CellsYahoo Finance·Nov 25, 2025
- Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia CellsYahoo Finance·Nov 21, 2025
- Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell LineYahoo Finance·Nov 12, 2025
- Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and ChemoYahoo Finance·Oct 23, 2025
- Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value GrowthYahoo Finance·Oct 21, 2025
- Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of CancerYahoo Finance·Oct 14, 2025
- Exchange-Traded Funds, Equity Futures Steady Pre-Bell as Investors Hope for Rate Cut, Await EarningsYahoo Finance·Oct 9, 2025
- Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer CellsYahoo Finance·Oct 9, 2025
- Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment ResistanceYahoo Finance·Oct 7, 2025
- Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other TherapiesYahoo Finance·Sep 18, 2025
- TELO Releases Cancer Suppressing ResultsYahoo Finance·Sep 9, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$1.33
Day High$0.00
Day Low$0.00
52 Week High$3.10
52 Week Low$1.05
52-Week Range
$1.05$3.10
$1.34
Fundamentals
Market Cap$92M
P/E Ratio—
EPS$-0.33
Dividend Yield—
Dividend / Share—
ROE-3.2%
Profit Margin—
Debt / Equity—
Trading
Volume129K
Avg Volume (10D)—
Shares Outstanding68.8M
About Telomir Pharmaceuticals Inc
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company is headquartered in Baltimore, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—